YOLFTbeta
Theralase Technologies Inc.

Theralase Technologies Inc.

TLT · V · Healthcare / Medical Devices

0.185CAD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.185
Open0.18
Day Range0.18 – 0.185
52-Week Range0.15 – 0.41
Volume109.79K
Market Cap57.44M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.01
Dividend Yield0.00%
Beta0.41
50-Day Avg0.205
200-Day Avg0.2471

About

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form of Ruvidar for the treatment of glio blastoma multiforme, a form of brain cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer, and muscle invasive bladder cancer; and Ruvidar, a topical treatment for herpes simplex virus-1 lesions and an extracorporeal treatment for lymphoma, leukemia, and multiple myeloma. The company also researches, develops, manufactures, and distributes Cool Laser Therapy systems to healthcare practitioners for the healing of pain. Theralase Technologies Inc. is based in Toronto, Canada.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Roger John Dumoulin-White B.Sc., P.Eng.
  • Employees0
  • Headquarters41 Hollinger Road, Toronto, ON, Canada, M4B 3G4, Canada
  • Websitehttps://www.theralase.com

Leadership

  • Mr. Roger John Dumoulin-White B.Sc., P.Eng.President, CEO & Chairman
  • Ms. Kristina Hachey CPACFO & Director
  • Dr. Arkady Mandel DSc., M.D., Ph.D.Chief Scientific Officer & Director
  • Mr. David M. Groves B.APresident of World Trade Division
  • Dr. Terry Ruch DVMEquine Medical Consultant

Financials

Income Statement

Currency: CAD2001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-2.38K27.72K657.35K1.21M1.44M1.56M2.17M2.36M2.04M2.03M1.82M1.20M1.38M1.95M1.92M2.34M1.73M964.05K929.12K780.64K1.14M1.07M1.03M816.47K
Growth (%)--+1067.24%+2271.23%+83.60%+19.09%+8.53%+39.01%+8.83%-13.53%-0.66%-10.00%-34.02%+14.70%+40.90%-1.35%+22.08%-25.97%-44.41%-3.62%-15.98%+45.85%-6.00%-3.45%-20.99%
Cost of Revenue--15.61K176.96K297.28K368.62K396.51K688.94K799.73K668.03K639.61K575.16K404.54K459.32K629.61K796.57K945.01K786.43K903.30K659.44K470.70K510.39K765.15K479.40K309.34K
Gross Profit-2.38K12.12K480.39K909.63K1.07M1.16M1.48M1.56M1.37M1.39M1.25M799.08K921.28K1.32M1.12M1.40M947.64K60.76K269.68K309.94K628.17K305.15K554.03K507.13K
Gross Margin-100.00%43.71%73.08%75.37%74.35%74.58%68.23%66.11%67.26%68.45%68.47%66.39%66.73%67.63%58.49%59.66%54.65%6.30%29.03%39.70%55.17%28.51%53.61%62.11%
Operating Expense--47.29K-41.57K418.65K897.63K780.75K68.95K368.28K1.32M169.37K2.85M-260.42K-304.76K-1.66M-3.89M-3.80M7.48M4.31M7.45M5.86M4.83M5.83M4.90M4.84M4.68M
Operating Income505.18K49.67K53.69K61.74K12.00K287.89K1.09M1.11M241.83K1.20M-1.46M1.51M1.10M2.58M5.21M4.92M-6.08M-3.37M-7.39M-5.59M-4.52M-5.20M-4.59M-4.29M-4.18M
Operating Margin-2091.28%193.65%9.39%0.99%20.03%70.16%51.24%10.25%58.96%-72.06%82.75%91.71%186.62%267.74%256.46%-259.75%-194.18%-766.20%-601.97%-578.87%-456.79%-429.25%-414.96%-511.39%
EBITDA403.03K-47.05K-49.25K83.23K124.06K-123.30K-926.94K-534.31K-66.25K-1.10M-1.41M-1.43M-1.02M-2.49M-5.08M-4.74M-5.82M-3.13M-7.13M-5.32M-4.24M-4.89M-4.31M-3.96M-3.81M
EBITDA Margin--1981.14%-177.67%12.66%10.28%-8.58%-59.42%-24.64%-2.81%-53.87%-69.33%-78.25%-84.57%-180.33%-261.16%-247.12%-248.63%-180.25%-739.72%-572.66%-543.49%-429.28%-402.51%-383.18%-467.03%
Net Income-175.07K-49.68K-49.65K59.34K12.89K-282.00K-1.11M-1.11M-241.58K-1.20M-1.45M-1.51M-1.15M-2.59M-5.21M-4.92M-6.09M-3.36M-7.43M-5.61M-4.42M-5.25M-4.57M-4.26M-4.12M
Net Income Margin--2091.92%-179.11%9.03%1.07%-19.62%-71.38%-51.27%-10.24%-58.79%-71.73%-82.75%-95.73%-187.42%-267.74%-256.46%-260.13%-193.58%-770.32%-603.60%-565.74%-460.97%-427.06%-411.84%-504.71%
R&D-------226.75K164.18K547.99K759.35K873.34K527.23K1.46M3.03M1.87M2.65M1.70M4.16M3.45M2.92M4.28M2.77M2.75M2.45M
R&D as % of Total Revenue-------10.46%6.96%26.86%37.46%47.87%43.80%105.41%155.73%97.33%113.25%98.25%431.48%371.13%374.66%376.01%259.02%266.46%300.37%
Interest Expense18.42K138828.44K8.17K5.33K4.53K10.32K5.62K2.25K5.77K23.00K42.77K19.54K7951988766312.36K9.68K5.34K21.25K30.41K24.14K42.07K
Interest Expense % of Total Revenue-0.55%3.18%1.28%0.68%0.37%0.29%0.48%0.24%0.11%0.28%1.26%3.55%1.42%0.04%0.01%0.00%0.04%1.28%1.04%0.68%1.87%2.84%2.34%5.15%

Balance Sheet

Currency: CAD2001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets146.59K98.07K614.96K1.22M3.55M3.68M3.71M3.18M4.19M3.24M1.41M1.13M2.68M3.82M7.10M6.24M3.32M3.56M15.47M10.02M5.94M4.16M3.28M3.25M3.49M
Total Liabilities9.56K10.72K215.75K161.52K158.99K313.74K335.12K794.79K703.90K706.35K955.71K1.20M920.99K511.75K785.66K549.74K1.28M2.57M1.61M857.13K874.79K1.07M1.37M1.18M1.72M
Total Equity137.03K87.35K399.21K1.05M3.39M3.37M3.37M2.39M3.49M2.53M455.16K-64.73K1.76M3.31M6.32M5.69M2.05M998.64K13.86M9.16M5.07M3.09M1.91M2.07M1.78M
Cash145.59K97.07K62.62K38.53K16.71K234.60K507.97K49.13K1.19M174.40K43.06K21.98K1.77M1.92M4.34M2.97M253.90K1.03M12.55M7.88M3.69M1.51M43.91K268.76K182.91K
Total Debt--125.00K78.24K30.00K70.00K-24.37K54.58K37.12K5.76K1.44K778-----144.62K92.34K35.72K473.62K386.88K--
Net Debt-145.59K-97.07K62.38K39.71K13.29K-164.60K-507.97K-24.76K-1.13M-137.28K-37.30K-20.54K-1.77M-1.92M-4.34M-2.97M-253.90K-1.03M-12.40M-7.79M-3.66M-1.03M342.97K-73.02K

Cash Flow

Currency: CAD2001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-82.62K-48.52K-192.39K-87.23K85.33K-25.78K-351.49K-351.19K-40.95K-1.02M-1.40M-606.72K-916.67K-3.63M-5.04M-4.88M-4.26M-1.22M-6.57M-4.45M-4.03M-5.13M-4.07M-3.33M-3.29M
Investing Cash Flow-------------92.45K-114.11K-248.50K-294.61K-410.37K-133.53K-533.21K-164.58K-100.82K-70.41K---
Financing Cash Flow229.36K-511.81K523.77K-70.83K118.00K719.32K-3.96K1.22M51.80K1.29M715.44K2.76M3.89M7.71M3.80M1.95M2.13M18.61M-57.56K-57.37K3.02M2.65M3.57M3.25M
Capital Expenditure0044.91K25.57K85.30K31.39K60.52K44.22K41.00K47.16K27.53K129.81K93.29K114.11K248.50K296.21K410.38K133.53K533.21K164.58K100.82K70.41K37.27K19.97K48.94K
Free Cash Flow-82.62K-48.52K-237.30K-112.80K28-57.17K-412.01K-395.42K-81.95K-1.06M-1.43M-736.52K-1.01M-3.74M-5.29M-5.18M-4.67M-1.35M-7.10M-4.61M-4.13M-5.20M-4.11M-3.35M-3.33M
FCF to OCF100.00%100.00%123.35%129.31%0.03%221.72%117.22%112.59%200.11%104.64%101.97%121.40%110.18%103.15%104.93%106.07%109.63%110.98%108.12%103.70%102.50%101.37%100.91%100.60%101.49%

Earnings

Report DateMar 31, 2007Jun 30, 2007Sep 30, 2007Dec 31, 2007Mar 31, 2008Jun 30, 2008Sep 30, 2008Dec 31, 2008Mar 31, 2009Jun 30, 2009Sep 30, 2009Dec 31, 2009Mar 31, 2010Aug 31, 2010Nov 29, 2010Dec 31, 2010Jun 29, 2011Aug 30, 2011Nov 28, 2011Dec 31, 2011May 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Aug 29, 2014Nov 28, 2014Dec 31, 2014May 29, 2015Aug 28, 2015Nov 27, 2015Dec 31, 2015Apr 29, 2016Aug 29, 2016Nov 29, 2016Dec 31, 2016May 1, 2017Aug 29, 2017Nov 29, 2017Feb 28, 2018May 30, 2018Jul 25, 2018Nov 29, 2018Feb 27, 2019May 5, 2019Aug 8, 2019Nov 29, 2019Feb 26, 2020May 29, 2020Aug 28, 2020Nov 26, 2020Dec 31, 2020May 28, 2021Aug 30, 2021Nov 29, 2021Dec 31, 2021May 30, 2022Aug 29, 2022Nov 29, 2022Apr 26, 2023Nov 28, 2023Mar 27, 2024May 30, 2024Aug 12, 2024Nov 27, 2024Mar 12, 2025May 29, 2025Aug 26, 2025Nov 27, 2025Dec 31, 2025May 29, 2026Aug 28, 2026Nov 10, 2026
EPS Estimate------------------------------0.01---0.01-0.01-0.01--0.02--0.02--0.01----------0.01-0.01-0.01--0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.000.00-0.00-0.00-0.00-0.00-0.01-0.01-0.00-
EPS Actual-0.00-0.00-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.00-0.000.00-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.00-0.01-0.01-0.01-0.00-0.00-0.01-0.01-0.01-0.02-0.01-0.01-0.01-0.02-0.01-0.01-0.01-0.01-0.01-0.01-0.02-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.02-0.01-0.01-0.010.00-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.00-0.00-0.01-0.00-0.00-0.00-0.00-0.00-
Surprise-----------------------------0.00%--0.00%0.00%-100.00%-45.50%-50.00%-0.00%---------0.00%-100.00%0.00%-0.00%100.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%50.00%0.00%---0.00%-233.33%0.00%0.00%60.00%20.00%0.00%-
Timing-------------After-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hours--------Pre-marketPre-market-After-hoursAfter-hoursPre-market-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-Pre-marketPre-marketAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap57.44M
Enterprise Value49.22M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales71.58
Price / Book7.94
EPS-0.01
Book Value0.023
Revenue (TTM)802.46K
Gross Profit (TTM)525.11K
EBITDA-3.65M
Profit Margin0.00%
Operating Margin-647.24%
Return on Equity-93.40%
Return on Assets-42.70%
Shares Outstanding310.48M
Shares Float291.33M
Beta0.41
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20081×
0.41Dec 29, 2008